Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
PI-88 is a new experimental drug that inhibits tumour growth by reducing the formation of new
blood vessels into tumours. Docetaxel is a standard second-line treatment offered to patients
with non-small-cell lung cancer who haven't responded to first-line therapies (platinum-based
drugs or radiotherapy). Of this group of patients, only 20% remain progression-free 6 months
after starting docetaxel treatment. The PR88202 study has been designed to compare two
different cancer treatments (docetaxel only, and docetaxel plus PI-88) and to work out which
is more effective against the cancer. It is hoped that the combination of PI-88 with
docetaxel will allow patients to extend the time it takes for their disease to progress, and
also to improve their quality of life.